SamerSKasbariMD

Oncology • Goldsboro, NC

Physician

Join to view full profile

Dr. Kasbari is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kasbari's full profile

Already have an account?

Office
203 Cox Blvd
Goldsboro, NC 27534
Phone+1 919-580-0000

Fax+1 919-580-0209

Education & Training

Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 2005 - 2008
Norwalk Hospital/Yale UniversityResidency, Internal Medicine, 2001 - 2004
St. George's University School of MedicineClass of 2001

Certifications & Licensure

NC State Medical License 2008 - 2025
CT State Medical License 2004 - 2006
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer Start of enrollment: 2011 Apr 07
Completed
Phase 2
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09
Completed
Phase 3

Publications & Presentations

PubMed

106 citations
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
David M. Waterhouse, Edward B. Garon, Jason C. Chandler, Michael McCleod, Maen A. Hussein
Journal of Clinical Oncology. 2020-09-10
Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cance...
Nagla Abdel Karim, Jieling Miao, Karen L Reckamp, Carl M Gay, Lauren A Byers
Journal of Thoracic Oncology. 2024-11-04
5 citations
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B.
Amy S Clark, Fangxin Hong, Richard S Finn, Angela M DeMichele, Edith P Mitchell
Clinical Cancer Research. 2023-04-14

Press Mentions

OneOncology Partners with Southeastern Medical Center to Expand Cancer Care in Eastern North CarolinaOctober 21st, 2024